CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 77 enrolled
Drug / intervention
Cilostazol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02554721
NCT02554721Phase 1Completed
CompareCT.gov

Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Sep 18, 2015·Updated Oct 13, 2021

In Brief

A Phase 1 clinical trial evaluating Cilostazol, Acetylsalicylic acid, and 1 other intervention for Healthy. Completed, enrolled 77 participants across 1 site.

Detailed Summary

The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo Platelet Function (PF) testing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 18, 2015
Enrollment StartAug 1, 2015
Primary CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.8 years ago

Interventions

Cilostazoldrug

Acetylsalicylic aciddrug

Clopidogreldrug